Exploratory pharmacovigilance with machine learning in big patient data: A focused scoping review

被引:5
作者
Kaas-Hansen, Benjamin Skov [1 ,2 ,6 ]
Gentile, Simona [3 ]
Caioli, Alessandro [4 ]
Andersen, Stig Ejdrup [5 ]
机构
[1] Copenhagen Univ Hosp, Dept Intens Care, Rigshosp, Copenhagen, Denmark
[2] Univ Copenhagen, Dept Publ Hlth, Sect Biostat, Copenhagen, Denmark
[3] Zealand Univ Hosp, Dept Radiol, Roskilde, Denmark
[4] Natl Inst Infect Dis Lazzaro Spallanzani, Dept Infect Dis Hepatol, Rome, Italy
[5] Zealand Univ Hosp Roskilde, Clin Pharmacol Unit, Roskilde, Denmark
[6] Blegdamsvej 9, DK-2100 Copenhagen, Denmark
关键词
administrative pharmacology; adverse drug reactions; machine learning; pharmacoepidemiology; postmarketing surveillance; HEALTH-CARE; INFORMATION; DESIGN; INFERENCE; REGISTRY; PRIVACY;
D O I
10.1111/bcpt.13828
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BackgroundMachine learning can operationalize the rich and complex data in electronic patient records for exploratory pharmacovigilance endeavours. ObjectiveThe objective of this review is to identify applications of machine learning and big patient data in exploratory pharmacovigilance. MethodsWe searched PubMed and Embase and included original articles with an exploratory pharmacovigilance purpose, focusing on medicinal interventions and reporting the use of machine learning in electronic patient records with >= 1000 patients collected after market entry. FindingsOf 2557 studies screened, seven were included. Those covered six countries and were published between 2015 and 2021. The most prominent machine learning methods were random forests, logistic regressions, and support vector machines. Two studies used artificial neural networks or naive Bayes classifiers. One study used formal concept analysis for association mining, and another used temporal difference learning. Five studies compared several methods against each other. The numbers of patients in most data sets were in the order of thousands; two studies used what can more reasonably be considered big data with >1 000 000 patients records. ConclusionDespite years of great aspirations for combining machine learning and clinical data for exploratory pharmacovigilance, only few studies still seem to deliver somewhat on these expectations.
引用
收藏
页码:233 / 241
页数:9
相关论文
共 49 条
  • [1] [Anonymous], 2004, Pharmacovigilance: ensuring the safe use of medicines
  • [2] [Anonymous], 2022, DATA ANAL REAL WORLD
  • [3] [Anonymous], 2021, OBS HLTH DAT SCI INF
  • [4] Pharmacovigilance: An Overview
    Beninger, Paul
    [J]. CLINICAL THERAPEUTICS, 2018, 40 (12) : 1991 - 2004
  • [5] BenTaieb A., 2019, DEEP LEARNING MODELS
  • [6] Chollet F., 2018, DEEP LEARNING PYTHON, DOI [10.1007/978-1-4842-2766-4, DOI 10.1007/978-1-4842-2766-4]
  • [7] Cohen JM., 2021, NORSK EPIDEMIOLOGI, V29, DOI [10.5324/nje.v29i1-2.4053, DOI 10.5324/NJE.V29I1]
  • [8] Cross-border flow of health information: is 'privacy by design' enough? Privacy performance assessment in EUBIROD
    Di Iorio, Concetta Tania
    Carinci, Fabrizio
    Brillante, Massimo
    Azzopardi, Joseph
    Beck, Peter
    Bratina, Natasa
    Cunningham, Scott G.
    De Beaufort, Carine
    Debacker, Noemi
    Jarosz-Chobot, Przemyslawa
    Jecht, Michael
    Lindblad, Ulf
    Moulton, Tony
    Metelko, Zeliko
    Nagy, Attila
    Olympios, George
    Pruna, Simion
    Roder, Michael
    Skeie, Svein
    Storms, Fred
    Benedetti, Massimo Massi
    [J]. EUROPEAN JOURNAL OF PUBLIC HEALTH, 2013, 23 (02) : 247 - 253
  • [9] Efron B, 2016, INST MATH STAT MG, P1, DOI 10.1017/CBO9781316576533
  • [10] Leveraging graph topology and semantic context for pharmacovigilance through twitter-streams
    Eshleman, Ryan
    Singh, Rahul
    [J]. BMC BIOINFORMATICS, 2016, 17